Bulletin for Prescribers | Genetic testing to inform tamoxifen prescribing
Approximately 70% of breast cancers are hormone-sensitive, expressing oestrogen or progesterone receptors. In this group of patients, hormone therapy is a long-established form of treatment. Tamoxifen is a selective oestrogen receptor modulator that has been a mainstay of hormone therapy for decades. It has a proven role in the prevention and treatment of pre- and post-menopausal breast cancer.
Guidance regarding the use of CYP2D6 metaboliser status to inform tamoxifen prescribing has been developed by a number of expert bodies, including the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, and the Canadian Pharmacogenomics Network for Drug Safety.
The Sonic PGx Panel report provides specific guidance for prescribing tamoxifen on the basis of the patient’s CYP2D6 metaboliser status and these international guidelines.
The Sonic PGx Panel is available nationally through Sonic Genetics. The cost is $197^ and a Medicare rebate is not available. The turnaround time is up to 7 business days, and results can be accessed electronically via Sonic Dx, by fax, or by phone. For further information, visit the Sonic Genetics website, www.sonicgenetics.com.au/pgx. Please email firstname.lastname@example.org should you have any enquiries. Locally, Clinpath's Sonic Genetics Product Liasion is Jill Hall